Exploratory Bioavailability of Two Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed and Fasting Conditions.

Phase 1

• Conditions: Type 2 diabetes mellitus; MedDRA version: 21.1Level: PTClassification code: 10067585Term: Type 2 diabetes mellitus Class: 100000004861; Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

• Registration Number: CTIS2023-507802-15-00
• Lead Sponsor: Institut De Recherches Internationales Servier IRIS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-08
• Study Completion: 2023-12-20
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified